mspipeline

RG2077 (CTLA4-IgG4m)

Geoff — Fri, 20 Jan 2012 03:38:25 +0000

I removed “RG2077 (aka CTLA4-IgG4m) (Immune Tolerance Network and Repligen)” from the phase 2 list because the Immune Tolerance Network is not pursuing development of this drug. According to a press release, “ACCLAIM is a follow-up trial to an earlier ITN-led open label phase I trial that was not conducted with abatacept but examined CTLA4IgG4m, a similar protein that blocks/reduces activation of T cells and helps regulate the immune system. Samia J. Khoury, M.D., a neurologist and co-director of the Partners MS Center at Brigham and Women’s Hospital in Boston, directed this trial. Dr. Khoury also is the principal investigator of the ACCLAIM trial. Results from the phase I trial showed that “CTLA4IgG4m was well tolerated and prevented or reduced Tcell activation in MS. The data suggested that it may be a promising approach to modifying the inflammatory process associated with MS.”

Pleneva (BGC20-0134)

Geoff — Fri, 20 Jan 2012 03:22:37 +0000

I removed “Pleneva (aka BGC20-0134) (BTG)” from the phase 2 list based on BTG’s Interim Results from September 2011, where they stated, “The development of BGC20-0134 (Pleneva), a potential licensing candidate, was halted following a Phase II study in which it did not meet the primary or secondary endpoints in a study in multiple sclerosis patients.”

Low Dose Naltrexone (LDN)

Geoff — Wed, 18 Jan 2012 06:25:24 +0000

I removed Low-dose naltrexone (aka LDN) (http://www.lowdosenaltrexone.org/ldn_trials.htm) from the phase 2 list because I could not find any evidence that it is currently being used in any trials for people with MS.

HP184 (Nerispirdine)

Geoff — Wed, 18 Jan 2012 05:54:59 +0000

I removed HP184 (aka nerispirdine) (Sanofi-Aventis) from the phase 2 list based on this corporate document (page 51) from 2011, which says that the phase 2 trial of nerispirdine for MS was abandoned.

Linoleic Acid (omega-6)

Geoff — Tue, 17 Jan 2012 05:25:06 +0000

I removed Linoleic Acid (omega-6) (University of Rochester) from the phase 1 list because the clinicaltrials.gov entry indicates that the trail has been terminated due to slow enrollment, leading to a funding cut.

Far Infrared Irradiation

Geoff — Tue, 17 Jan 2012 05:14:21 +0000

Based on this web page, I removed “Far Infrared Irradiation (GAAD Medical Research Institute, Canada)” http://www.clinicaltrials.gov/ct2/show/NCT00674934, from the phase 1 list. It appears that the study’s sponsor went out of business in 2010.

ARX-424

Geoff — Sun, 08 Jan 2012 04:50:48 +0000

I added ARX-424 to the phase 1 list after LuCi pointed out that this isn’t the same thing as Merck Serono’s extended release interferon.

MOR103

Geoff — Sun, 08 Jan 2012 04:48:07 +0000

I added MOR103 to the phase 1 list, based on this press release from December 21, announcing the commencement of a phase 1b trial.

Masitinib

Geoff — Tue, 13 Sep 2011 01:45:43 +0000

I moved Masitinib from phase 2 to phase 3 based on this recent press release from AB Science.

E2007

Geoff — Tue, 13 Sep 2011 01:44:24 +0000

I added E2007 back on to the phase 2 list (after deleting it in 2006) based on a tip, and the pipeline document on Eisai’s Research & Development page.